优化uPAR靶向放射性肽的组织分布:迈向放射性核素治疗
本研究基于AE105九肽合成六种经白蛋白结合基团修饰的uPAR靶向放射性肽,用177Lu标记后在体外评估稳定性、白蛋白结合性能及uPAR亲和力,并在HEK-uPAR荷瘤裸鼠中进行生物分布与SPECT/CT显像。结果显示这些肽的人血浆白蛋白结合亲和力较[177Lu]Lu-DOTA-AE105高11–155倍,uPAR亲和力KD为31–42 nM,移植瘤摄取在注射后4小时达6.0–16% IA/g,为对照的7–18倍,其中[177Lu]Lu-uPAR-11被选为最有利的临床转化候选。
要点
- 白蛋白结合基团修饰使uPAR靶向肽的人血浆白蛋白结合亲和力较对照高11–155倍。
- 移植瘤摄取在注射后4小时达6.0–16% IA/g,为[177Lu]Lu-DOTA-AE105的7–18倍。
- [177Lu]Lu-uPAR-11因组织分布最优被选为最具临床转化前景的候选。
核心结论
- 综合组织分布表现,[177Lu]Lu-uPAR-11是最有利于临床转化的候选肽。
- 后续研究将聚焦[177Lu]Lu-uPAR-11在荷瘤小鼠中的治疗潜力。
研究设计与样本
- 基于AE105九肽合成uPAR-11、uPAR-12、uPAR-14、uPAR-15、uPAR-17和uPAR-18,均经对甲苯基白蛋白结合基团及不同连接臂和螯合剂修饰。
- 用177Lu标记上述肽,在HEK-uPAR细胞中评估稳定性、白蛋白结合性能与uPAR结合亲和力。
- 在HEK-uPAR荷瘤裸鼠中进行生物分布与SPECT/CT显像,并与[177Lu]Lu-DOTA-AE105比较。
主要发现
- 上述放射性肽在人血浆中的白蛋白结合亲和力较[177Lu]Lu-DOTA-AE105高11–155倍。
- uPAR结合亲和力KD为31–42 nM,与[177Lu]Lu-DOTA-AE105的20 ± 1 nM相近。
- 注射后4小时HEK-uPAR移植瘤摄取为6.0–16% IA/g,较[177Lu]Lu-DOTA-AE105高7–18倍。
- [177Lu]Lu-uPAR-11、[177Lu]Lu-uPAR-15和[177Lu]Lu-uPAR-18中白蛋白结合基团旁的PEG间隔臂使移植瘤摄取增加。
- [177Lu]Lu-uPAR-12以烷烃间隔臂替换PEG后出现不利的高血池滞留,[177Lu]Lu-uPAR-17以DOTAGA替代DOTA后出现不利的肾脏滞留。
临床怎么用
- 提示白蛋白结合基团修饰可改善uPAR靶向放射性肽的肿瘤摄取,[177Lu]Lu-uPAR-11可作为进一步治疗研究的优先候选。
- 连接臂与螯合剂的选择显著影响血池与肾脏滞留,优化设计时需权衡间隔臂与螯合剂类型。
局限性
- 研究仅在HEK-uPAR荷瘤裸鼠中完成生物分布与显像,尚未报告治疗疗效数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to develop radiopeptides for targeting the urokinase-type plasminogen activator receptor (uPAR) modified with an albumin-binding moiety to improve their tissue distribution profiles. METHODS: uPAR-11, uPAR-12, uPAR-14, uPAR-15, uPAR-17 and uPAR-18 were synthesized based on the AE105 nonapeptide which was modified with the p-tolyl-based albumin binder and variable linker entities and chelators. The 177Lu-labeled peptides were evaluated in vitro with regard to their stability, albumin-binding properties and uPAR-binding affinity using HEK-uPAR cells. Biodistribution and SPECT/CT imaging studies were performed with HEK-uPAR xenografted nude mice. The acquired data were compared to those obtained with [177Lu]Lu-DOTA-AE105. RESULTS: The radiopeptides showed 11‒155-fold higher albumin-binding affinity in human blood plasma than [177Lu]Lu-DOTA-AE105. The uPAR-binding affinity reached KD values of 31‒42 nM, similar to the KD value of 20 ± 1 nM determined for [177Lu]Lu-DOTA-AE105. Accumulation in the HEK-uPAR xenograft was 6.0-16% IA/g at 4 h p.i., which was 7‒18-fold higher than that of [177Lu]Lu-DOTA-AE105. PEG spacers next to the albumin binder as exemplified in [177Lu]Lu-uPAR-11, [177Lu]Lu-uPAR-15 and [177Lu]Lu-uPAR-18 led to increased xenograft accumulation while their replacement with an alkane spacer in [177Lu]Lu-uPAR-12 led to unfavorably high blood retention. A diaminopropionic acid to connect the different entities did not improve the tissue distribution profile of [177Lu]Lu-uPAR-14 as compared to other peptides which were designed with a lysine residue. The use of a DOTAGA chelator instead of a DOTA resulted in unfavorable kidney retention of [177Lu]Lu-uPAR-17. CONCLUSION: In view of a clinical translation, [177Lu]Lu-uPAR-11 emerged as the most favorable candidate. Future studies will, thus, focus on the therapeutic potential of [177Lu]Lu-uPAR-11 in tumor-bearing mice.
引用
- Vaccarin C, Beyer D, Schmid JV, et al. Optimizing uPAR-targeting radiopeptides for improved tissue distribution: progress towards radionuclide therapy. Eur J Nucl Med Mol Imaging. 2025. PMID: 41143984. doi:10.1007/s00259-025-07602-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。